FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Cancer News

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Back to Cancer Insights